CS 27100
Alternative Names: CS-27100Latest Information Update: 03 Nov 2020
At a glance
- Originator Chipscreen Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein tyrosine phosphatase non-receptor type 11 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Immunological disorders
Most Recent Events
- 21 Oct 2020 Preclinical trials in Cancer in China (unspecified route) before October 2020 (Chipscreen Biosciences pipeline, October 2020)
- 21 Oct 2020 Preclinical trials in Immunological disorders in China (unspecified route) before October 2020 (Chipscreen Biosciences pipeline, October 2020)